Single‑use fermenters are becoming an increasingly viable alternative to stainless steel, offering less time is spent on equipment preparation and qualification prior to start-up as well as routine maintenance and requalification of the equipment.
The process design proven for one fermentor system is not always directly transferrable to other system formats without adaptation. Here, we compare the performance of the XDR‑500 MO fermentor with the XDR‑50 MO system.
This study, performed with a prototype system, is designed to confirm the system’s suitability for concentration and diafiltration steps to high final concentrations up to 150 g/L.
This case study shares the work of GE’s Fast Trak Services team to help accelerate development of a process for cGMP production of material for toxicology studies.
The present study investigates the beneficial effect of spiking HyClone™ ActiPro™ basal medium with HyClone Cell Boost™ 7a and Cell Boost 7b feed supplements on growth and productivity of a recombinant Chinese hamster ovary (CHO) cell line.
Fed-batch culture is commonly employed to maximize cell and product concentrations in upstream mammalian cell culture processes. Typical standard platform processes rely on fixed-volume bolus feeding of concentrated supplements at regular intervals. However, such static approaches might result in over- or underfeeding. To mimic more closely the dynamics of a fed-batch culture, we developed a dynamic feeding strategy responsive to the actual nutrient needs of a mAb-producing recombinant Chinese hamster ovary (CHO) cell line.
In this webinar Joaquina Mascarenhas, Ph.D. of Milliporesigma will discuss the following...
Among the primary causes for attrition in early clinical development are safety and pharmacology issues. In the case of biopharmaceuticals, immunogenic and hypersensitivity reactions are perhaps the largest contributors to such early clinical failures
It is estimated that only one out of every 1,000 preclinical candidates reaches the commercial market. The ability to assess the “developability” of a therapeutic candidate in late discovery through clinical phases of development can be an extremely powerful tool to enhance the chance of clinical success. Screening of potential candidates in the discovery process will help to reduce costs, risk (attrition) and overall development time. Being able to assess the manufacturability and safety of the drug candidate, before large investments are made, allows companies to focus on the most promising candidate and maximize R&D spending.
Thanks for your interest in BioSpa™ 8 Automated Incubator. We are excited to share the following product demonstrations with you so you can see how BioSpa links liquid handling, reading and imaging together for unattended workflow automation. We’ll provide examples of typical assay workflows to help you understand exactly how BioSpa can help you take control of your cell assays.
Achieving peak performance of protein-producing cell lines in biopharmaceutical manufacturing requires careful selection of cell culture media. Media supplements and optimally designed feeding strategies can further improve titers and deliver desired product quality characteristics.